Cellino is using AI and machine learning to scale production of stem cell therapies
TechCrunch
SEPTEMBER 22, 2021
But today, such cell therapies are out of reach for most people because the process of cell production hasn’t been automated or made scalable and efficient. In this manual process, you’d see a yield of about 10% to 20% of cells that would be able to pass the final quality assurance tests required for human transplant.
Let's personalize your content